Vitonnix lands first institutional capital in seed round led by Inflection Point Ventures
What's the deal? Vitonnix, a UK-developed preventive healthcare startup, has raised its first institutional capital in a seed round led by Inflection Point VenturesDealroom has a profile for this one. Try Dealroom →. Participants include Bollywood actors Riteish DeshmukhDealroom has a profile for this one. Try Dealroom → and Boman IraniDealroom has a profile for this one. Try Dealroom →, singer Jaspinder Narula, and film producer Madhu Mantena, alongside practising doctors.
What does it do? The company makes SubliSpray, a range of sublingual nutritional sprays designed for absorption through the oral mucosa. Each formulation is built for the spray itself — with attention to dose consistency, taste, and stability — rather than adapted from a tablet.
Why now? Founded by three practising doctors, Vitonnix spent more than a decade on research — including three completed clinical studies — before taking outside money. It has already sold millions of bottles, built largely on founder capital.
What's the endgame? The funds will strengthen senior leadership, build a consumer-growth engine, expand distribution, and enter new international markets. Vitonnix plans to launch an initial range of 10 products, with a UK rollout slated for 2026.
The startup was developed in the UK but keeps its research, formulation, and manufacturing base in India, with global operations run from London and Birmingham. Its spray systems are engineered in Germany, and it has filed patent applications for its bottle designs and formulations.
What they're saying: "Vitonnix stood out because it's more than a consumer supplement brand," said Vinay Bansal, co-founder of Inflection Point Ventures. "It pairs clinical leadership with differentiated delivery technology and proprietary formulations."
Co-founder Dr Prashant Jindal, a UK-based refractive eye surgeon, said the company "began in the United Kingdom with a clinical question, but the ambition was always global."
The signal: A decade-old, founder-funded healthcare brand taking its first outside cheque reflects a model of capital discipline that is increasingly rare in early-stage startups — and a growing investor appetite for preventive healthcare with clinical grounding.
Read more: the9thestate.com
Image credit: Generated with Gemini
